Compare REXR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REXR | NUVL |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 256 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.8B |
| IPO Year | N/A | 2021 |
| Metric | REXR | NUVL |
|---|---|---|
| Price | $34.32 | $123.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $41.00 | ★ $134.75 |
| AVG Volume (30 Days) | 2.5M | ★ 4.2M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.09 | N/A |
| Revenue Next Year | $2.99 | $1,239.49 |
| P/E Ratio | $43.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.14 | $71.14 |
| 52 Week High | $44.38 | $123.69 |
| Indicator | REXR | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 66.42 |
| Support Level | $32.17 | $97.99 |
| Resistance Level | $36.33 | $123.62 |
| Average True Range (ATR) | 0.85 | 0.58 |
| MACD | -0.01 | 0.66 |
| Stochastic Oscillator | 55.90 | 99.45 |
Rexford Industrial Realty Inc is a real estate investment trust focused on owning, operating and acquiring industrial properties in Southern California infill markets. Its goal is to generate attractive risk-adjusted returns for the stockholders by providing superior access to industrial property investments and mortgage debt investments secured by industrial property in high-barrier Southern California infill markets. The company generates revenue from rental income derived from properties in its portfolio.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.